residual disease

residual disease

Oncology Malignant cells or neoplasia that remains after any form–chemotherapy, surgery, RT–of 1º treatment
References in periodicals archive ?
Food and Drug Administration (FDA) will review data supporting the BLINCYTO (blinatumomab) supplemental Biologics License Application (sBLA) for the treatment of patients with minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (ALL) at a meeting on March 7, 2018.
The primary endpoint is overall survival and secondary endpoints include morphologic complete remission (CR) rate, cytogenetic complete remission, and complete remission without minimal residual disease.
The most of the patients having no recurrence and residual disease, the patients having local residual disease and distant metastasis chose yellow, red and black colors, respectively.
The 1,260 patients with a static Physician Global Assessment (PGA) score of 1, or almost clear, at week 12 had significantly greater residual disease in terms of involved body surface area, fewer symptom-free days, and greater health-related quality of life impairment than did the 1,097 participants who achieved a static PGA of 0.
It is thought that such relapses result from a sub-clinical level of residual leukaemia known as minimal residual disease (MRD).
The panelists also recommend re-imaging and re-evaluating patients 6-8 weeks after the completion of chemoradiation, with possible resection or biopsy of the primary tumor site, and limited groin resection of imaged residual disease
The editors have organized the contributions that make up the main body of the text in seven parts devoted to genomic alterations, targeting MYCN, apoptosis and angioneogenesis, molecular-targeted therapy studies, immunology, minimal residual disease, and a wide variety of other related subjects.
The other 24 patients with residual disease responded to the treatment according to the size of the residual disease left.
Improvements of these approaches could be expected to significantly impact the ability to define complete responses to chemotherapy, potentially eliminate minimal residual disease (MRD), and provide earlier detection of disease relapse, opening an earlier window for patient treatment.
One of the labs at the centre is currently developing a test known as deduction of minimal residual disease (MRD) for detection of cancer cells in a patient's body following treatment.
Among the topics are principles of flow cytometry, limitations, acute leukaemia, myelodysplastic syndromes and myeloproliferative neoplasms, minimal residual disease, and reactive and non-neoplastic phenomena.